|
US4045485A
(en)
|
1968-07-02 |
1977-08-30 |
Syntex Corporation |
Naphthyl acetaldehyde derivatives; methods of use thereof; and processes for the preparation thereof
|
|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
|
US5360811A
(en)
|
1990-03-13 |
1994-11-01 |
Hoechst-Roussel Pharmaceuticals Incorporated |
1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
|
|
JP3545461B2
(ja)
|
1993-09-10 |
2004-07-21 |
エーザイ株式会社 |
二環式ヘテロ環含有スルホンアミド誘導体
|
|
AU4596096A
(en)
|
1994-09-06 |
1996-03-27 |
Banyu Pharmaceutical Co., Ltd. |
Novel carbapenem derivative
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
CA2269561C
(en)
|
1998-04-22 |
2007-06-05 |
Dainippon Ink And Chemicals, Inc. |
Naphthalene derivative and liquid crystal composition comprising the same
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
IL131264A0
(en)
|
1999-08-05 |
2001-01-28 |
Yeda Res & Dev |
Photochromic naphthopyran compounds
|
|
DE60037345T2
(de)
|
1999-12-10 |
2008-11-13 |
Pfizer Products Inc., Groton |
Pyrrolo(2,3-d)pyrimidin-Verbindungen
|
|
DE10002509A1
(de)
|
2000-01-21 |
2001-07-26 |
Gruenenthal Gmbh |
Substituierte Glutarimide
|
|
EP1259514B9
(en)
|
2000-02-28 |
2005-11-09 |
Sugen, Inc. |
3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
WO2002020740A2
(en)
|
2000-09-08 |
2002-03-14 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
DE60217322T2
(de)
|
2001-04-27 |
2007-10-04 |
Zenyaku Kogyo K.K. |
Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
PT1536827E
(pt)
|
2002-08-14 |
2009-03-20 |
Silence Therapeutics Ag |
Utilização de proteína cinase n beta
|
|
AU2004228668B2
(en)
|
2003-04-03 |
2011-10-27 |
Park Funding, Llc |
PI-3 kinase inhibitor prodrugs
|
|
ES2382377T3
(es)
|
2003-05-30 |
2012-06-07 |
Gemin X Pharmaceuticals Canada Inc. |
Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
|
|
EP1692153A4
(en)
|
2003-07-03 |
2007-03-21 |
Univ Pennsylvania |
INHIBITION OF EXPRESSION OF SYK-KINASE
|
|
JP4398263B2
(ja)
|
2004-01-13 |
2010-01-13 |
富士通株式会社 |
経路設計方法
|
|
WO2005113556A1
(en)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
PL1888550T3
(pl)
|
2005-05-12 |
2014-12-31 |
Abbvie Bahamas Ltd |
Promotory apoptozy
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
US7989622B2
(en)
|
2005-10-07 |
2011-08-02 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors and methods of their use
|
|
JP5191391B2
(ja)
|
2005-11-01 |
2013-05-08 |
ターゲジェン インコーポレーティッド |
キナーゼのビ−アリールメタ−ピリミジン阻害剤
|
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
|
UA96283C2
(uk)
|
2005-12-23 |
2011-10-25 |
Зіланд Фарма А/С |
Модифіковані міметики лізину
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
WO2007129161A2
(en)
|
2006-04-26 |
2007-11-15 |
F. Hoffmann-La Roche Ag |
Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
|
|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
|
US20100279316A1
(en)
|
2007-01-19 |
2010-11-04 |
Leonid Gorelik |
Antibodies to Phosphorylated IRAK4
|
|
KR101566840B1
(ko)
|
2007-03-12 |
2015-11-06 |
와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 |
페닐 아미노 피리미딘 화합물 및 이의 용도
|
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
GB0706793D0
(en)
|
2007-04-05 |
2007-05-16 |
Evotec Ag |
Compounds
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
EP2219671A4
(en)
|
2007-11-09 |
2011-02-09 |
Salk Inst For Biological Studi |
USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
|
|
US10047066B2
(en)
|
2007-11-30 |
2018-08-14 |
Newlink Genetics Corporation |
IDO inhibitors
|
|
US20090171093A1
(en)
|
2007-12-28 |
2009-07-02 |
Yoshio Takeuchi |
3'-Fluoro-5'-hydroxythalidomide and derivatives thereof
|
|
HUE029767T2
(en)
|
2008-03-11 |
2017-04-28 |
Incyte Holdings Corp |
JAK inhibitor azetidine and cyclobutane derivatives
|
|
CA2722159C
(en)
|
2008-04-24 |
2016-04-05 |
Newlink Genetics Corporation |
Substituted phenylimidazole compounds and their use as ido inhibitors
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
US8921037B2
(en)
|
2008-12-16 |
2014-12-30 |
Bo Han |
PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
JP2012254939A
(ja)
|
2009-10-07 |
2012-12-27 |
Astellas Pharma Inc |
オキサゾール化合物
|
|
EP2493862B1
(en)
|
2009-10-28 |
2016-10-05 |
Newlink Genetics Corporation |
Imidazole derivatives as ido inhibitors
|
|
ES2722300T3
(es)
|
2009-12-10 |
2019-08-09 |
Hoffmann La Roche |
Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
|
|
PL3202460T3
(pl)
|
2010-02-11 |
2019-12-31 |
Celgene Corporation |
Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
US9169323B2
(en)
|
2010-03-05 |
2015-10-27 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
US8114621B2
(en)
|
2010-03-12 |
2012-02-14 |
Saladax Biomedical Inc. |
Lenalidomide and thalidomide immunoassays
|
|
HRP20190047T1
(hr)
|
2010-05-04 |
2019-02-22 |
Five Prime Therapeutics, Inc. |
Protutijela koja se vežu na csf1r
|
|
EP2575884B1
(en)
|
2010-06-03 |
2018-07-18 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of hidradenitis suppurativa (hs)
|
|
CN103153335A
(zh)
|
2010-06-30 |
2013-06-12 |
布兰代斯大学 |
小分子靶定的蛋白质降解
|
|
CN110003219A
(zh)
|
2010-07-13 |
2019-07-12 |
弗·哈夫曼-拉罗切有限公司 |
作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
RU2632900C2
(ru)
|
2010-11-19 |
2017-10-11 |
Лиганд Фармасьютикалс Инкорпорейтед |
Гетероциклические амины и их применение
|
|
CA2823837A1
(en)
|
2010-12-07 |
2012-06-14 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
BR112013015460B1
(pt)
|
2010-12-20 |
2022-01-25 |
Merck Serono S.A. |
Derivados de indazolil triazol, kit, e composição farmacêutica
|
|
WO2012097013A1
(en)
|
2011-01-10 |
2012-07-19 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
US9169260B2
(en)
|
2011-03-22 |
2015-10-27 |
Merck Sharp & Dohme Corp. |
Amidopyrazole inhibitors of interleukin receptor-associated kinases
|
|
NO2694640T3
(enExample)
|
2011-04-15 |
2018-03-17 |
|
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
WO2013042137A1
(en)
|
2011-09-19 |
2013-03-28 |
Aurigene Discovery Technologies Limited |
Bicyclic heterocycles as irak4 inhibitors
|
|
US9221809B2
(en)
|
2011-10-31 |
2015-12-29 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
RU2658603C2
(ru)
|
2011-12-15 |
2018-06-21 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против человеческого csf-1r и их применения
|
|
JP6126131B2
(ja)
|
2012-01-10 |
2017-05-10 |
ニンバス アイリス， インコーポレイテッド |
Ｉｒａｋ阻害剤およびその使用
|
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
|
CN104169275B
(zh)
|
2012-01-13 |
2017-06-09 |
百时美施贵宝公司 |
用作激酶抑制剂的三唑取代的吡啶化合物
|
|
EP2802576B1
(en)
|
2012-01-13 |
2018-06-27 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
|
ES2575604T3
(es)
|
2012-01-13 |
2016-06-29 |
Bristol-Myers Squibb Company |
Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa
|
|
KR20140127855A
(ko)
|
2012-02-06 |
2014-11-04 |
제넨테크, 인크. |
Csf1r 억제제를 사용하는 조성물 및 방법
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
RU2670743C9
(ru)
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
JP6189434B2
(ja)
|
2012-07-10 |
2017-08-30 |
アレス トレーディング ソシエテ アノニム |
ピリミジンピラゾリル誘導体
|
|
WO2014011906A2
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2014011902A1
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2014011911A2
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
AU2013299627C1
(en)
|
2012-08-09 |
2018-05-31 |
Celgene Corporation |
Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
WO2014044622A1
(en)
|
2012-09-19 |
2014-03-27 |
F. Hoffmann-La Roche Ag |
2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer
|
|
WO2014058685A1
(en)
|
2012-10-08 |
2014-04-17 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
EP2903613B1
(en)
|
2012-10-08 |
2017-11-22 |
Merck Sharp & Dohme Corp. |
Pyrazole derivatives useful as inhibitors of irak4 activity
|
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
KR102233252B1
(ko)
|
2012-11-08 |
2021-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
|
|
BR112015009850A2
(pt)
|
2012-11-08 |
2017-07-11 |
Bristol Myers Squibb Co |
compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
HUE032863T2
(en)
|
2013-02-07 |
2017-11-28 |
Merck Patent Gmbh |
Piridazinonamid derivatives
|
|
HRP20171302T1
(hr)
|
2013-02-07 |
2017-10-20 |
Merck Patent Gmbh |
Makrociklički derivati piridazinona
|
|
US9617282B2
(en)
|
2013-03-15 |
2017-04-11 |
Biogen Ma Inc. |
Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases
|
|
WO2014142237A1
(ja)
|
2013-03-15 |
2014-09-18 |
日本ゼオン株式会社 |
中空重合体粒子の水性分散液およびその製造方法
|
|
CN106232122A
(zh)
|
2013-09-27 |
2016-12-14 |
林伯士艾瑞斯公司 |
Irak抑制剂和其用途
|
|
PT3052485T
(pt)
|
2013-10-04 |
2021-10-22 |
Infinity Pharmaceuticals Inc |
Compostos heterocíclicos e suas utilizações
|
|
WO2015068856A1
(en)
|
2013-11-08 |
2015-05-14 |
Takeda Pharmaceutical Company Limited |
Pyrazole for the treatment autoimmune disorders
|
|
MX2016006432A
(es)
|
2013-11-18 |
2016-07-19 |
Hoffmann La Roche |
Tetrahidro-benzodiazepinonas.
|
|
US10233176B2
(en)
|
2013-11-27 |
2019-03-19 |
Signalchem Lifesciences Corporation |
Aminopyridine derivatives as TAM family kinase inhibitors
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
UY35935A
(es)
|
2014-01-03 |
2015-06-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
|
|
EP3092226B1
(en)
|
2014-01-10 |
2019-03-13 |
Aurigene Discovery Technologies Limited |
Indazole compounds as irak4 inhibitors
|
|
LT3466955T
(lt)
|
2014-01-13 |
2021-02-25 |
Aurigene Discovery Technologies Limited |
Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
|
|
MA39749A
(fr)
|
2014-03-17 |
2017-01-25 |
Hoffmann La Roche |
Dérivés de pipéridine-dione
|
|
AU2015233654B2
(en)
|
2014-03-19 |
2018-12-06 |
Boehringer Ingelheim International Gmbh |
Heteroaryl Syk inhibitors
|
|
DK3126330T3
(en)
|
2014-04-04 |
2019-04-23 |
Pfizer |
BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
RU2738833C9
(ru)
|
2014-04-14 |
2022-02-28 |
Арвинас, Оперэйшнз, Инк. |
Имидные модуляторы протеолиза и способы их применения
|
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
KR20160145803A
(ko)
|
2014-04-22 |
2016-12-20 |
님버스 아이리스 인코포레이티드 |
Irak 억제제 및 이의 용도
|
|
AU2015275730A1
(en)
|
2014-06-20 |
2016-12-15 |
Aurigene Discovery Technologies Limited |
Substituted indazole compounds as IRAK4 inhibitors
|
|
EP3827836A1
(en)
|
2014-06-27 |
2021-06-02 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
|
US10246456B2
(en)
|
2014-07-18 |
2019-04-02 |
Biogen Ma Inc. |
IRAK4 inhibiting agents
|
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
US9932350B2
(en)
|
2014-09-30 |
2018-04-03 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
EP3200790B1
(en)
|
2014-09-30 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
EP3200788B1
(en)
|
2014-09-30 |
2019-09-18 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
US9969749B2
(en)
|
2014-09-30 |
2018-05-15 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
JP6787892B2
(ja)
|
2014-11-20 |
2020-11-18 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
Ｉｒａｋインヒビターとしてのヘテロアリール化合物及びその使用
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2016144849A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
|
WO2016144847A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of irak4 activity
|
|
WO2016144848A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of irak4 activity
|
|
US10329294B2
(en)
|
2015-03-12 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of IRAK4 activity
|
|
EP3270917A4
(en)
|
2015-03-18 |
2018-08-08 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
LT3286181T
(lt)
|
2015-04-22 |
2021-04-26 |
Rigel Pharmaceuticals, Inc. |
Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
|
|
TW201701879A
(zh)
|
2015-04-30 |
2017-01-16 |
拜耳製藥公司 |
Ｉｒａｋ４抑制劑組合
|
|
CA2988414C
(en)
|
2015-06-04 |
2023-09-26 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
EP3313840B1
(en)
|
2015-06-24 |
2019-07-24 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
|
CN105085620B
(zh)
|
2015-06-25 |
2018-05-08 |
中山大学附属第一医院 |
一种靶向泛素化降解Smad3的化合物
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2017004133A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
BR112017028269A2
(pt)
|
2015-07-13 |
2018-09-04 |
Arvinas Inc |
composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
|
|
WO2017009650A1
(en)
|
2015-07-14 |
2017-01-19 |
Mission Therapeutics Limited |
Cyanopyrrolidines as dub inhibitors for the treatment of cancer
|
|
JP2018524372A
(ja)
|
2015-07-15 |
2018-08-30 |
アウリジーン ディスカバリー テクノロジーズ リミテッド |
Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
|
|
CN108024971A
(zh)
|
2015-07-15 |
2018-05-11 |
奥列基因发现技术有限公司 |
作为irak-4抑制剂的取代的氮杂化合物
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
HUE053705T2
(hu)
|
2015-08-27 |
2021-07-28 |
Pfizer |
Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
|
|
GB201516243D0
(en)
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
BR112018003812B1
(pt)
|
2015-09-18 |
2024-04-30 |
Merck Patent Gmbh |
Compostos de heteroarila como inibidores de irak, seu uso, composição farmacêutica, e kit
|
|
CN108602776B
(zh)
|
2015-09-18 |
2021-12-03 |
默克专利有限公司 |
用作irak抑制剂的杂芳基化合物及其用途
|
|
EP3355922A2
(en)
|
2015-10-02 |
2018-08-08 |
Dana Farber Cancer Institute, Inc. |
Combination therapy of bromodomain inhibitors and checkpoint blockade
|
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
SG10202112628UA
(en)
|
2015-11-30 |
2021-12-30 |
Anacor Pharmaceuticals Inc |
Topical pharmaceutical formulations for treating inflammatory-related conditions
|
|
CN108473498B
(zh)
|
2015-12-22 |
2021-11-02 |
豪夫迈·罗氏有限公司 |
作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
|
|
WO2017108744A1
(de)
|
2015-12-22 |
2017-06-29 |
Bayer Pharma Aktiengesellschaft |
Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
|
WO2017117474A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
|
WO2017117473A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molescules for her3 degradation and methods of use
|
|
US11427561B2
(en)
|
2016-01-20 |
2022-08-30 |
Biogen Ma Inc. |
IRAK4 inhibiting agents
|
|
WO2017148902A1
(de)
|
2016-03-03 |
2017-09-08 |
Bayer Pharma Aktiengesellschaft |
Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
|
BR112018068906A2
(pt)
|
2016-03-16 |
2019-01-22 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
US10759808B2
(en)
|
2016-04-06 |
2020-09-01 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
SG11201808728QA
(en)
|
2016-04-06 |
2018-11-29 |
Univ Michigan Regents |
Mdm2 protein degraders
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
|
CN118436801A
(zh)
|
2016-05-20 |
2024-08-06 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
|
WO2017207385A1
(de)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EP3475263B1
(en)
|
2016-06-27 |
2022-12-28 |
Rigel Pharmaceuticals, Inc. |
2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
|
JP2019196309A
(ja)
|
2016-09-15 |
2019-11-14 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
CN110506039A
(zh)
|
2016-10-11 |
2019-11-26 |
阿尔维纳斯股份有限公司 |
用于雄激素受体靶向降解的化合物和方法
|
|
US10925868B2
(en)
|
2016-11-10 |
2021-02-23 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
|
AU2017363313B2
(en)
|
2016-11-22 |
2021-06-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
|
|
JP2020505327A
(ja)
|
2016-12-23 |
2020-02-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
|
|
CN108322937B
(zh)
|
2017-01-18 |
2020-08-11 |
上海诺基亚贝尔股份有限公司 |
无线接入网中用于网络切片的资源分配方法和编排器
|
|
BR112019015312A2
(pt)
|
2017-01-26 |
2020-03-10 |
Arvinas Operations, Inc. |
Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
|
|
IL312367A
(en)
|
2017-01-31 |
2024-06-01 |
Arvinas Operations Inc |
Cereblon ligands and bifunctional compounds comprising the same
|
|
TW202340194A
(zh)
|
2017-02-16 |
2023-10-16 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
PT3621960T
(pt)
|
2017-05-11 |
2021-09-16 |
Bristol Myers Squibb Co |
Tienopiridinas e benzotiofenos úteis como inibidores de irak4
|
|
PH12019502605A1
(en)
|
2017-05-23 |
2020-10-26 |
Theravance Biopharma R&D Ip Llc |
Glucuronide prodrugs of janus kinase inhibitors
|
|
JP7202315B2
(ja)
|
2017-05-26 |
2023-01-11 |
キャンサー・リサーチ・テクノロジー・リミテッド |
ベンズイミダゾロン由来のｂｃｌ６阻害剤
|
|
WO2018226542A1
(en)
|
2017-06-09 |
2018-12-13 |
Arvinas, Inc. |
Modulators of proteolysis and associated methods of use
|
|
CN110740733A
(zh)
|
2017-06-16 |
2020-01-31 |
豪夫迈·罗氏有限公司 |
Irak4介导的疾患和病症的诊断和治疗方法
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
WO2019075136A1
(en)
|
2017-10-10 |
2019-04-18 |
Aldeyra Therapeutics, Inc. |
TREATMENT OF INFLAMMATORY DISORDERS
|
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
|
WO2019084026A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
|
|
WO2019094773A1
(en)
|
2017-11-10 |
2019-05-16 |
The Regents Of The University Of Michigan |
Ash1l inhibitors and methods of treatment therewith
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
EP3710443A1
(en)
*
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
CA3085645C
(en)
|
2017-12-13 |
2024-01-16 |
Shanghaitech University |
Alk protein degraders and their use in cancer therapy
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11542251B2
(en)
|
2018-02-14 |
2023-01-03 |
Dana-Farber Cancer Institute, Inc. |
IRAK degraders and uses thereof
|
|
CA3090417A1
(en)
|
2018-02-23 |
2019-08-29 |
Dana-Farber Cancer Institute, Inc. |
Small molecules for inducing selective protein degradation and uses thereof
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2020010210A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
CA3102996A1
(en)
|
2018-07-20 |
2020-01-23 |
Dana-Farber Cancer Institute, Inc. |
Degraders that target proteins via keap1
|
|
CN117285467A
(zh)
|
2018-07-31 |
2023-12-26 |
罗索肿瘤学公司 |
喷雾干燥的分散体和制剂
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
|
|
JP7472103B2
(ja)
|
2018-08-22 |
2024-04-22 |
クルゲン（シャンハイ），インク． |
トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法
|
|
CN110862375B
(zh)
|
2018-08-27 |
2022-10-25 |
深圳铂立健医药有限公司 |
吡唑化合物及其药物组合物和应用
|
|
CN112969696B
(zh)
|
2018-11-02 |
2024-06-11 |
达纳-法伯癌症研究公司 |
乙酰化书写器抑制剂的开发及其用途
|
|
CA3119773A1
(en)
*
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
MA54755A
(fr)
|
2019-01-18 |
2021-11-24 |
Biogen Ma Inc |
Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
|
|
CN120574283A
(zh)
|
2019-04-05 |
2025-09-02 |
凯麦拉医疗公司 |
Stat降解剂和其用途
|
|
US20230072658A1
(en)
|
2019-06-10 |
2023-03-09 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020251974A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
WO2020251969A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2020264490A1
(en)
|
2019-06-28 |
2020-12-30 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US20240059674A1
(en)
|
2019-06-28 |
2024-02-22 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021011634A1
(en)
|
2019-07-15 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2021011631A1
(en)
|
2019-07-15 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Fused-glutarimide crbn ligands and uses thereof
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021011871A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
WO2021018118A1
(en)
|
2019-07-29 |
2021-02-04 |
Janssen Pharmaceutica Nv |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 1 proteins
|
|
WO2021053555A1
(en)
|
2019-09-16 |
2021-03-25 |
Novartis Ag |
Glue degraders and methods of use thereof
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
US20230219945A1
(en)
|
2019-12-17 |
2023-07-13 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US20230122219A1
(en)
|
2020-02-03 |
2023-04-20 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021168197A1
(en)
|
2020-02-19 |
2021-08-26 |
Nurix Therapeutics, Inc. |
Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
|
|
WO2021222366A1
(en)
|
2020-04-28 |
2021-11-04 |
Kymera Therapeutics, Inc. |
Irak inhibitors and uses thereof
|
|
US20230250110A1
(en)
|
2020-06-03 |
2023-08-10 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
WO2021257914A1
(en)
|
2020-06-17 |
2021-12-23 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CN116133692A
(zh)
|
2020-07-30 |
2023-05-16 |
凯麦拉医疗公司 |
治疗突变淋巴瘤的方法
|
|
JP7591301B2
(ja)
|
2020-08-05 |
2024-11-28 |
リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド |
タンパク質を標的とし、分解するための化合物ならびにその調製方法および使用
|
|
WO2022087216A1
(en)
|
2020-10-21 |
2022-04-28 |
Kymera Therapeutics, Inc. |
Double degraders and uses thereof
|
|
US20230192655A1
(en)
|
2020-10-26 |
2023-06-22 |
Shanghai Leadingtac Pharmaceutical Co., Ltd. |
Indazole derivative, and preparation method therefor and use thereof
|
|
CN114437035A
(zh)
|
2020-11-06 |
2022-05-06 |
海思科医药集团股份有限公司 |
一种抑制并降解irak4的化合物及其药物组合物和药学上的应用
|
|
IL303458A
(en)
|
2020-12-09 |
2023-08-01 |
Kymera Therapeutics Inc |
IRAK joints and their uses
|
|
CN116867758A
(zh)
|
2020-12-30 |
2023-10-10 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
WO2022161414A1
(zh)
|
2021-01-26 |
2022-08-04 |
成都茵创园医药科技有限公司 |
芳香化合物、含其的药物组合物及其应用
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
US12171768B2
(en)
|
2021-02-15 |
2024-12-24 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
US20240383887A1
(en)
|
2021-05-07 |
2024-11-21 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
WO2022266258A1
(en)
|
2021-06-15 |
2022-12-22 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of irak-4
|
|
JP2024524480A
(ja)
|
2021-07-01 |
2024-07-05 |
ハンチョウ、ヘルズン、セラピューティクス、カンパニー、リミテッド |
ブルトン型チロシンキナーゼ及びその突然変異体の分解剤、組成物並びにそれらの応用
|
|
EP4367113A1
(en)
|
2021-07-07 |
2024-05-15 |
Biogen MA Inc. |
Compounds for targeting degradation of irak4 proteins
|
|
US20250018046A1
(en)
|
2021-07-07 |
2025-01-16 |
Biogen Ma Inc |
Compounds for targeting degradation of irak4 proteins
|
|
CN117813307A
(zh)
|
2021-08-18 |
2024-04-02 |
新锐思生物制药股份有限公司 |
白介素-1受体相关激酶的双官能降解物及其治疗用途
|
|
CA3229646A1
(en)
|
2021-08-23 |
2023-03-02 |
Zhengqing YE |
Irak4 degradation agent, and preparation method therefor and use thereof
|
|
TWI899502B
(zh)
|
2021-09-08 |
2025-10-01 |
大陸商南京明德新藥研發有限公司 |
戊二醯亞胺類化合物與其應用
|
|
US20240400547A1
(en)
|
2021-09-26 |
2024-12-05 |
Medshine Discovery Inc. |
2,6-piperidinedione compound and application thereof
|
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
|
TW202333670A
(zh)
|
2022-01-04 |
2023-09-01 |
大陸商海思科醫藥集團股份有限公司 |
抑制並降解irak4的化合物及其藥物组合物和藥學上的應用
|
|
US20230277519A1
(en)
|
2022-01-14 |
2023-09-07 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CA3243560A1
(en)
|
2022-01-31 |
2023-08-03 |
Kymera Therapeutics, Inc. |
Iraqi Degradation Agents and Their Uses
|
|
WO2023192586A1
(en)
|
2022-03-31 |
2023-10-05 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2023186069A1
(zh)
|
2022-03-31 |
2023-10-05 |
石药集团中奇制药技术（石家庄）有限公司 |
一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途
|
|
AU2023253700A1
(en)
|
2022-04-12 |
2024-11-28 |
Genzyme Corporation |
Use of an irak4 modulator for gene therapy
|
|
JP2025513850A
(ja)
|
2022-04-12 |
2025-04-30 |
ジェンザイム・コーポレーション |
遺伝子治療のためのｉｒａｋ４モジュレーターの使用
|
|
CN117164583A
(zh)
|
2022-05-20 |
2023-12-05 |
斯迈旭(苏州)生物科技有限公司 |
一种靶向irak4蛋白降解的化合物及其应用
|
|
AU2023282477A1
(en)
|
2022-06-09 |
2024-12-19 |
Beone Medicines I Gmbh |
Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use
|
|
WO2023241644A1
(zh)
|
2022-06-15 |
2023-12-21 |
杭州多域生物技术有限公司 |
一种五元并六元化合物、制备方法、药物组合物和应用
|
|
WO2024020084A1
(en)
|
2022-07-20 |
2024-01-25 |
Bristol-Myers Squibb Company |
Heteroaryl compounds as ligand directed degraders of irak4
|
|
WO2024020522A1
(en)
|
2022-07-22 |
2024-01-25 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of irak-4
|
|
CN116925085B
(zh)
|
2022-07-23 |
2026-03-31 |
成都茵创园医药科技有限公司 |
Irak降解剂及其用途
|
|
CN117777126A
(zh)
|
2022-09-29 |
2024-03-29 |
武汉人福创新药物研发中心有限公司 |
作为irak4降解剂的咪唑并吡啶类化合物及其用途
|
|
CN120303270A
(zh)
|
2022-10-13 |
2025-07-11 |
凯麦拉医疗公司 |
Irak4降解剂的盐形式
|
|
AU2023371864A1
(en)
|
2022-11-04 |
2025-04-17 |
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. |
Irak4 degradation agent and use thereof
|
|
AU2023398975A1
(en)
|
2022-12-13 |
2025-06-12 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CN120641423A
(zh)
|
2023-03-03 |
2025-09-12 |
上海齐鲁制药研究中心有限公司 |
Irak4降解剂及其应用
|
|
CN118946561A
(zh)
|
2023-03-10 |
2024-11-12 |
标新生物医药科技(上海)有限公司 |
新颖的e3泛素连接酶配体、蛋白降解剂及其应用
|
|
CN120981450A
(zh)
|
2023-04-03 |
2025-11-18 |
上海汇伦医药股份有限公司 |
靶向蛋白降解化合物及其制备方法和应用
|
|
TW202508568A
(zh)
|
2023-04-07 |
2025-03-01 |
瑞典商阿斯特捷利康公司 |
Ｉｒａｋ４蛋白水解靶向嵌合體
|
|
AU2024312190A1
(en)
|
2023-06-23 |
2025-07-03 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2025024305A2
(en)
|
2023-07-21 |
2025-01-30 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CN118047758A
(zh)
|
2024-01-31 |
2024-05-17 |
西南交通大学 |
一种靶向bcl6蛋白降解的嵌合体分子及其应用
|
|
CN118440056A
(zh)
|
2024-04-28 |
2024-08-06 |
杭州医学院 |
基于crbn配体诱导irak4降解的化合物及其制备方法和应用
|